These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20571354)

  • 1. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
    Zhu LB; Xu Q; Hong CY; Yue Z; Zhang Y; Ye HN; Yuan Y
    Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN
    Acta Oncol; 2007; 46(3):361-6. PubMed ID: 17450472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
    Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
    J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P; Wang YD; Cheng J; Chen JC; Ha MW
    Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter--effect on telomerase expression and telomere length maintenance in non-small cell lung cancer.
    Hsu CP; Hsu NY; Lee LW; Ko JL
    Eur J Cancer; 2006 Jul; 42(10):1466-74. PubMed ID: 16737810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.
    Pepe C; Hasan B; Winton TL; Seymour L; Graham B; Livingston RB; Johnson DH; Rigas JR; Ding K; Shepherd FA;
    J Clin Oncol; 2007 Apr; 25(12):1553-61. PubMed ID: 17442999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A study on the expression of CASP9 gene and its polymorphism distribution in non-small cell lung cancer].
    Lou Y; Fang CQ; Li JH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):59-62. PubMed ID: 17285546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer.
    Marín MS; López-Cima MF; García-Castro L; Pascual T; Marrón MG; Tardón A
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1788-93. PubMed ID: 15533908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.